Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Single-arm Exploratory Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA Non-Small Cell Lung Cancer

NCT07043907 is registered in ClinicalTrials.gov with Shenzhen Celconta Life Science Co., Ltd. as lead sponsor.

NCT NCT07043907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07043907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Single-arm Exploratory Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA Non-Small Cell Lung Cancer
Lead sponsor
Shenzhen Celconta Life Science Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 8, 2025
Completion date
June 18, 2029
Enrollment
115 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage iiia non-small cell lung cancer